Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
|Articles|September 29, 2009
Intertek — Stability Studies for Biopharmaceuticals
Timely and accurate evaluation of identity, strength, quality, purity and potency are key to successfully managing stability and release programs.
Advertisement
Timely and accurate evaluation of identity, strength, quality, purity and potency are key to successfully managing stability and release programs. With pharmaceutical stability storage capabilities in UK and Ireland, integrated with GMP analytical capabilities, Intertek scientists can design, initiate and conduct all aspects of your stability and batch release studies with specialist capabilities for biopharmaceuticals. Intertek stability studies for protein therapeutics, for example, can involve a range of technologies including; peptide fingerprinting / sequencing by LC-MS/MS, SDS-PAGE, IEF, amino acid analysis, CE, glycan analysis and more.
Intertek will be exhibiting at ICSE, Madrid in Oct 2009. Please Visit stand 8BIO40 to find out more
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement